ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
 PMID: 26122273       2015       Hepatology (Baltimore, Md.)
Result: As expected, ETV at 1 to 1,000 nM concentrations failed to block HBVETV-RL180M/S202G/M204V replication; even the highest concentration (1,000 nM) of ETV failed to achieve 50% signal reduction as shown in.
Result: By contrast, both CAdA and CdG significantly blocked HBVETV-RL180M/S202G/M204V replication in a dose-response fashion.
Result: CAdA and CdG block HBVETV-RL180M/S202G/M204V and HBVADV-RA181T/N236T replication.


  Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
 PMID: 26005376       2015       International journal of medical sciences
Abstract: Moreover, no LAM-resistant rtM204I/V or ETV-resistant variants were detected during the 27-36 months of combination therapy.
Discussion: In addition, no LAM-resistant rtM204I/V or ETV-resistant variants were selected during 27-36 months of combination therapy.
Discussion: It should be noted that during ADV-ETV combination rescue therapy, although the replication of ADV-resistant variants, rtA181V and/or rtN236T, was fully inhibited and no LAM-resistant rtM204I/V or ETV-resistant variants were selected after 27-36 months of combination rescue therapy, HBV DNA reduction was delayed even with potent ADV-ETV c


  [The drug resistance mutation detection and relevant factors analysis of HBV P region in chronic hepatitis B patients in Weifang City, Shandong Province].
 PMID: 25997324       2015       Bing du xue bao
Abstract: M204V/I mutation mostly existed in the form of joint L180M mutation, the mutation rate was age-related.


  Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.
 PMID: 25982306       2015       The Brazilian journal of infectious diseases
Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.


  Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Cote d'Ivoire.
 PMID: 25852125       2015       Antiviral therapy
Abstract: Among 11/127 (8.7%) patients with high-level persistent viraemia (last HBV VL: >=10(5) copies/ml), only two harboured incident LAM-resistance mutations at positions rtV173L+rtL180M+rtM204V with no patient exhibiting TDF/FTC-resistance.


  Characterization of novel entecavir resistance mutations.
 PMID: 25817219       2015       Journal of hepatology
Abstract: RESULTS: RtI163V and rtA186T mutations were detected together with LAMr (rtL180M and rtM204V) at VBT.


  [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
 PMID: 25751382       2015       Zhonghua gan zang bing za zhi
Abstract: RESULTS: The incidence of rtA181T across the study population was 4.1% (165/3, 013), and most of the rtAl 81T-positive patients had received adefovir and/or lamivudine.Forty percent (66/165) of the rtA 181T cases were single mutants and treatment responsive, 46.1% (76/165) included the adefovir-resistant mutation rtA 181 V/N236T, 12.1% (20/165) included the lamivudine-resistant mutation rtM204V/rtM2041, and 1.8% (3/165) included multidrug-resistant mutations.Interestingly, 73.9% (122/165) of the rtA181T-positive samples were detected with co-existing wild-type nucleotides at the site.


  New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
 PMID: 25732900       2015       Journal of medical virology
Abstract: Classical lamivudine resistance mutations (rtM204V/rtL180M) were present in one naive-treatment patient infected with genotype G.


  Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
 PMID: 25712861       2015       Journal of medical virology
Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).


  High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
 PMID: 25654813       2015       Antiviral therapy
Abstract: Three major patterns of mutations in HBV polymerase gene, namely single (rtM204V), double (rtL180M+rtM204V) and triple (rtV173L+rtL180M+rtM204V) mutations, are associated with 3TC-resistance; additionally, the triple mutation has vaccine-escape potential due to a corresponding change in overlapping surface gene.



Browser Board

 Co-occurred Entities




   Filtrator